继发于胰腺癌的皮肤转移。
Cutaneous metastases secondary to pancreatic cancer.
机构信息
Kei Horino, Hiroshi Takamori, Yoshiaki Ikuta, Osamu Nakahara, Akira Chikamoto, Takatoshi Ishiko, Toru Beppu, Hideo Baba, Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto 860-8556, Japan.
出版信息
World J Gastrointest Oncol. 2012 Jul 15;4(7):176-80. doi: 10.4251/wjgo.v4.i7.176.
AIM
To evaluate prognoses after cutaneous metastases, derived from pancreatic cancer.
METHODS
We treated two patients with cutaneous metastases from pancreatic cancer. We reviewed 40 reported patients in addition to our cases and analyzed clinical features of cutaneous metastases from pancreatic cancer.
RESULTS
The median survival time (MST) was 5 mo after diagnoses of cutaneous metastases. The cumulative 2-year survival rate was 3.5%. The most frequent site of cutaneous metastases was the umbilicus. The MST of patients who were treated with chemotherapy or chemoradiotherapy (CRT) was 6.5 mo, which was statistically longer in comparison to patients without treatment. Prognoses of cutaneous metastases are similar to other metastatic sites from pancreatic cancer. Receiving chemotherapy or CRT was the only prognostic factor of cutaneous metastases from pancreatic cancer.
CONCLUSION
The prognoses of cutaneous metastases are similar to other metastatic pancreatic cancers. Receiving chemotherapy or CRT was the only prognostic factor of cutaneous metastases from pancreatic cancer.
目的
评估源于胰腺癌的皮肤转移的预后。
方法
我们治疗了两例胰腺癌皮肤转移患者。我们复习了除我们病例之外的 40 例报道病例，并分析了胰腺癌皮肤转移的临床特征。
结果
皮肤转移诊断后的中位生存时间（MST）为 5 个月。累积 2 年生存率为 3.5%。皮肤转移最常见的部位是脐部。接受化疗或放化疗（CRT）治疗的患者 MST 为 6.5 个月，与未治疗患者相比，该时间明显更长。皮肤转移的预后与胰腺癌其他转移部位相似。接受化疗或 CRT 是胰腺癌皮肤转移的唯一预后因素。
结论
皮肤转移的预后与胰腺癌其他转移部位相似。接受化疗或 CRT 是胰腺癌皮肤转移的唯一预后因素。
Zotero 插件